Men’s health studies presented at ENDO 2017 included a possible prostate cancer treatment and the potential of hormone therapy to prevent frailty.
Three studies from ENDO 2017 focused on improving patient care through brain stimulation, an artificial pancreas system, and videoconferencing.
Researchers sought to discover the specific physiological pathways of fibroblast growth factor 21.
Research presented at ENDO 2017 explored options to reduce complications in patients with diabetes and microalbuminuria and patients with cystic fibrosis.
Studies presented at ENDO 2017 examined the impact of sleep disorders on gestational diabetes, bone formation, and adolescents with and without diabetes.
Researchers investigated possible differences in the function of the striatum both before and after the development of obesity.
Researchers compared time to onset of diabetes in a group of patients with obesity and pre-diabetes treated with liraglutide or placebo.
You won’t want to miss these top sessions and new features at this year’s Endocrinology Society’s annual meeting, April 1-4, in Orlando, FL.
Studies include drug-free remission of T2DM, and the impact of hyperglycemia and hypoglycemia on cardiovascular health.
A small pilot study is the first to report on bone health in people with an at least 50-year history of type 1 diabetes.
How well do waist-to-height ratios calculated using NHANES and WHO protocols indicate cardiometabolic risk in youth with diabetes?
Our March list includes Testosterone Trials results, self-management in patients transitioning to adult care, and cancer mortality risk with diabetes.
Research has shown the beneficial effects of empagliflozin on all-cause and CV mortality. Does the same hold true for another SGLT2 inhibitor?
How would you treat glucose excursions in a patient treated with prednisone?
When choosing a healthcare provider, many consumers value online reviews of physicians. How can you make the most of this opportunity?